Cannabis rescheduling, explained
In April 2026 the federal government moved FDA-approved and state-licensed medical marijuana to Schedule III, while most cannabis stays Schedule I pending a broader hearing.
Last updated 2026-06-20 · Not legal advice
As of June 2026, cannabis is no longer treated uniformly under federal law. An April 23, 2026 Justice Department order placed FDA-approved marijuana drug products and marijuana sold under a qualifying state medical-marijuana license into Schedule III of the Controlled Substances Act, effective April 28, 2026. All other marijuana — including adult-use (recreational) cannabis and unlicensed or bulk marijuana — remains in Schedule I, and a separate DEA hearing on broader rescheduling is set to begin June 29, 2026.
Timeline
What actually changed in April 2026
Following a December 18, 2025 executive order directing the Attorney General to expedite rescheduling, Acting Attorney General Todd Blanche issued a final order on April 23, 2026 moving two narrow categories from Schedule I to Schedule III: marijuana contained in an FDA-approved drug product, and marijuana subject to a state medical-marijuana license. The change took effect upon publication in the Federal Register on April 28, 2026. It does not reschedule all marijuana; unlicensed crops, bulk marijuana, and adult-use cannabis stay in Schedule I.
What Schedule III changes
For the covered medical-cannabis products, Schedule III status lifts the Internal Revenue Code Section 280E penalty, which bars businesses trafficking Schedule I and II substances from deducting ordinary expenses like rent, payroll, and marketing; the order also directs the IRS to consider retrospective 280E relief. Schedule III is a recognized-medical-use category, which can ease federally registered research by letting qualified practitioners source product from licensed suppliers. Some banks may become more willing to provide certain services, though major card networks are expected to remain cautious. The change applies to products within the federally legal medical framework, not to the broader market.
What it does NOT change
This is not legalization. Adult-use (recreational) cannabis remains in Schedule I and federally illegal, and state-legal commercial cannabis outside the FDA-approved or state-medical-license categories is unaffected. Schedule III still requires DEA registration and federal controls; it does not authorize over-the-counter sales or interstate commerce. State medical and adult-use programs continue to operate under state law, which remains distinct from federal law.
What happens next
The April order also restarted a formal rulemaking process to consider moving all marijuana from Schedule I to Schedule III, reviving a proposal first issued as a May 2024 notice of proposed rulemaking that had been stayed in early 2025. An expedited DEA administrative hearing, presided over by Chief Administrative Law Judge Derek C. Julius, is scheduled to begin June 29, 2026 in Arlington, Virginia and to conclude no later than July 15, 2026. The hearing addresses only whether the remaining categories of marijuana should be downscheduled; any broader change would still require a final rule after the hearing record is complete.
Frequently asked questions
Is marijuana legal federally now?
No. Marijuana is not federally legal. As of June 2026, only FDA-approved marijuana drug products and state-licensed medical marijuana have moved to Schedule III, which remains a controlled, regulated category. All other marijuana stays in Schedule I and remains federally illegal.
What is Schedule III?
Schedule III is a category of the federal Controlled Substances Act for drugs with an accepted medical use and a lower potential for abuse than Schedule I or II substances (examples include ketamine and certain anabolic steroids). Schedule III substances are still controlled and require DEA registration to manufacture, distribute, or dispense.
Does rescheduling legalize weed?
No. Rescheduling is not legalization and not decriminalization. It reclassifies certain medical cannabis products within the federal drug-control system but does not authorize recreational use, retail sales outside the regulated framework, or interstate commerce.
What does it mean for cannabis businesses (280E)?
For businesses handling the rescheduled medical-cannabis products, Schedule III removes the Section 280E penalty that bars deducting ordinary business expenses, and the IRS was directed to weigh retrospective relief. Businesses outside that category — including state-legal adult-use operators — remain subject to Section 280E and federal illegality.
What does it mean for medical patients?
The change is regulatory and tax-focused rather than a direct change to patient access, which is still governed by individual state medical-marijuana programs. Over time, Schedule III status may support more federally registered research into medical cannabis. This is general information, not medical or legal advice.
When will broader rescheduling happen?
It is not yet decided. A DEA administrative hearing on moving all marijuana to Schedule III begins June 29, 2026 and is set to conclude by July 15, 2026, after which a final rule would still be required. There is no guaranteed outcome or fixed date for any broader change.
See where your state stands → cannabis laws by state, or browse cannabis jobs.
Sources: justice.gov, federalregister.gov, dea.gov. General information for adults 21+, not legal advice.